Back to Search Start Over

Safety of BNT162b2 and CoronaVac during pregnancy on birth outcomes and neonatal mortality: a cohort study from Brazil.

Authors :
Florentino, Pilar Tavares Veras
Cerqueira-Silva, Thiago
Carvalho, Luciana Freire De
Alves, Flávia Jôse Oliveira
Oliveira, Vinicius De Araújo
Aguilar, Gislani Mateus Oliveira
Prado, Rodrigo De Sousa
Soranz, Daniel
Pearce, Neil
Boaventura, Viviane
Werneck, Guilherme Loreiro
Penna, Gerson Oliveira
Barreto, Mauricio Lima
Garcia, Márcio Henrique De Oliveira
Barral-Netto, Manoel
Paixão, Enny Santos da
Source :
International Journal of Epidemiology; Dec2023, Vol. 52 Issue 6, p1708-1715, 8p
Publication Year :
2023

Abstract

Background COVID-19 vaccines have been shown to protect pregnant individuals against mild and severe COVID-19 outcomes. However, limited safety data are available for inactivated (CoronaVac) and mRNA (BNT162b2) vaccines during pregnancy regarding their effect on birth outcomes and neonatal mortality, especially in low- and middle-income countries. Methods We conducted a retrospective population-based cohort study in Rio de Janeiro, Brazil, with 17 513 singleton live births conceived between 15 May 2021 and 23 October 2021. The primary exposure was maternal vaccination with CoronaVac or mRNA BNT162b2 vaccines and sub-analyses were performed by the gestational trimester of the first dose and the number of doses given during pregnancy. The outcomes were pre-term birth (PTB), small for gestational age (SGA), low birthweight (LBW), low Apgar 5 and neonatal death. We used the Cox model to estimate the hazard ratio (HR) with a 95% CI and applied the inverse probability of treatment weights to generate adjusted HRs. Results We found no significant increase in the risk of PTB (HR: 0.98; 95% CI 0.88, 1.10), SGA (HR: 1.09; 95% CI 0.96, 1.27), LBW (HR: 1.00; 95% CI 0.88, 1.14), low Apgar 5 (HR: 0.81; 95% CI 0.55, 1.22) or neonatal death (HR: 0.88; 95% CI 0.56, 1.48) in women vaccinated with CoronaVac or BNT162b2 vaccines. These findings were consistent across sub-analyses stratified by the gestational trimester of the first dose and the number of doses given during pregnancy. We found mild yet consistent protection against PTB in women who received different vaccine platforms during the third trimester of pregnancy (any vaccines, HR: 0.78; 95% CI 0.63, 0.98; BNT162b2, HR: 0.75; 95% CI 0.59, 0.99). Conclusions This study provides evidence that COVID-19 vaccination in all trimesters of pregnancy, irrespective of the vaccine type, is safe and does not increase the risk of adverse birth outcomes or neonatal deaths. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03005771
Volume :
52
Issue :
6
Database :
Complementary Index
Journal :
International Journal of Epidemiology
Publication Type :
Academic Journal
Accession number :
174466283
Full Text :
https://doi.org/10.1093/ije/dyad120